MedTrace Logo

PEACE: Pediatric Antifungal Comparative Effectiveness

NCT01869829 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2022-01-28

No results posted yet for this study

Summary

The overarching objective is to develop new evidence-based treatment guidelines for invasive fungal diseases in children. To accomplish that, this protocol will focus on two specific aims: 1) Compare the effectiveness of echinocandin versus amphotericin B or triazole antifungal therapy for pediatric invasive candidiasis and for the subset of patients with invasive candidemia; 2) Characterize the incidence rate of inpatient pediatric invasive candidiasis per hospital admissions.

Conditions

  • Pediatric Invasive Candidiasis

Interventions

DRUG

Observational antifungal therapy

Observational study of primary antifungal therapy utilized and outcomes, including: fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin All agents are given as standard of care.

Sponsors & Collaborators

Principal Investigators

  • William J Steinbach, MD · Duke University

  • Theoklis E Zaoutis, MD MSCE · Children's Hospital of Philadelphia

Eligibility

Min Age
120 Days
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • United States
  • Canada
  • Colombia
  • Greece
  • India
  • Italy
  • Saudi Arabia
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01869829 on ClinicalTrials.gov